Timothy McAlindon, MD
Rheumatology · Worcester, MANPI 1518931625
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $115,303 of the $129,139 with a category attached, or 89.3%. Pfizer accounts for 61.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $45,458 and has fallen 91.2% since, to $4,000 in 2025. Among rheumatology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $2690.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$79K
- GRT US Holding, Inc.$12K
- Sanofi-aventis U.S. LLC$12K
- Averitas Pharma Inc.$6K
- Lilly USA, LLC$5K
- Noven Therapeutics, LLC$5K
- plus $11K from 6 others
Across 15 payments — averaging $5638.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$36K
- Takeda Pharmaceuticals U.S.A., Inc.$34K
- Pfizer$7K
- Boehringer Ingelheim International GmbH$5K
- Novartis$2K
What the payments were for
- Consulting fees$115,30389%
- Speaking & faculty fees$8,3116%
- Travel & lodging$4,5744%
- Food & beverage$9511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $78,909 |
| GRT US Holding, Inc. | 5 | $11,862 |
| Sanofi-aventis U.S. LLC | 2 | $11,754 |
| Averitas Pharma Inc. | 5 | $5,551 |
| Lilly USA, LLC | 1 | $5,250 |
| Noven Therapeutics, LLC | 5 | $5,196 |
| Eli Lilly | 1 | $4,000 |
| UCB SA | 1 | $2,000 |
| Sanofi | 1 | $1,749 |
| Noven Pharmaceuticals, Inc. | 1 | $1,500 |
| Anika Therapeutics, Inc. | 1 | $1,250 |
| Sanofi US Services Inc. | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$129,139 in reported general payments places this provider in the 95th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 18 | $613 |
| Diclofenac Sodium | 11 | $369 |
| Prednisone | 28 | $271 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Worcester
- Jonathan KayWorcester$191K
- Roberto CaricchioWorcester$79K
- Charles BirbaraWorcester$24K
- Jonathan CheahWorcester$16K
- Leslie HarroldWorcester$16K
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Ronald RapoportFall River$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.